CLINICAL TRIAL

ELX/TEZ/IVA for Cystic Fibrosis

Waitlist Available · Any Age · All Sexes · Cleveland, OH

This study is evaluating whether a drug combination can improve lung function in people with cystic fibrosis.

See full description

About the trial for Cystic Fibrosis

Eligible Conditions
Fibrosis · Cystic Fibrosis

Treatment Groups

This trial involves 2 different treatments. ELX/TEZ/IVA is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
IVA
DRUG
ELX/TEZ/IVA
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ivacaftor
FDA approved
Elexacaftor
FDA approved

Eligibility

This trial is for patients born any sex of any age. There are 2 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
Completed the study drug treatment in the parent study, or had study drug interruption(s) but completed all the study visits up to the last scheduled visit in the parent study. show original
Key
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: From Baseline up to Week 196
Screening: ~3 weeks
Treatment: Varies
Reporting: From Baseline up to Week 196
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: From Baseline up to Week 196.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether ELX/TEZ/IVA will improve 1 primary outcome and 12 secondary outcomes in patients with Cystic Fibrosis. Measurement will happen over the course of From Baseline up to Week 192.

Absolute change in body mass index (BMI)
FROM BASELINE UP TO WEEK 192
FROM BASELINE UP TO WEEK 192
Absolute change in sweat chloride (SwCl)
FROM BASELINE UP TO WEEK 192
FROM BASELINE UP TO WEEK 192
Absolute change in height-for-age z-score
FROM BASELINE UP TO WEEK 192
FROM BASELINE UP TO WEEK 192
Absolute change in lung clearance index 2.5 (LCI 2.5)
FROM BASELINE UP TO WEEK 192
FROM BASELINE UP TO WEEK 192
Number of pulmonary exacerbations (PEx)
FROM BASELINE UP TO WEEK 192
FROM BASELINE UP TO WEEK 192
Absolute change in weight-for-age z-score
FROM BASELINE UP TO WEEK 192
FROM BASELINE UP TO WEEK 192
See More

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is cystic fibrosis?

Cystic fibrosis can be diagnosed through a number of different tests including sweat test, X-ray, genetic test, echocardiogram, CT scan, or lung transplant as shown in this resource. Treatments can differ depending on how severe the disease is.\n

Anonymous Patient Answer

How many people get cystic fibrosis a year in the United States?

There was an estimated 7.6 million new CF cases in 2017 across the US, making the disease one of the most prevalent pediatric and adult-specific diagnoses in the country. In 2018, 4,569 children and adults were diagnosed with CF in the US. A national population health analysis reveals that in the US there are approximately 3,800 people diagnosed with CF a year. As a result, CF is by far the most disabling and life-threatening condition affecting people of all ethnic backgrounds. In 2016, more than $2.8 billion in new costs, totaling nearly $17 billion, were due to the cost of new CF diagnosis from 2012 to 2018, when this analysis is based. Because this is an estimated loss of $8.

Anonymous Patient Answer

What are common treatments for cystic fibrosis?

Cystic fibrosis patients often need to be monitored for changes in lung function following bronchiectasis treatment or other therapy, such as medications, to evaluate optimal therapeutic strategies, so that treatment can be adjusted depending on lung disease severity and progression. The diagnosis of cystic fibrosis often follows, in a minority of cases, a CFTR Genetic test in addition to PFTs.\n

Anonymous Patient Answer

What are the signs of cystic fibrosis?

For most children with CF, signs are present during their first year of life, beginning with abdominal distension and vomiting. Other signs include chest pain, breathlessness, hoarseness, loss of weight and diarrhea. Children with worsening symptoms can develop bacterial infections of the lungs, which could explain their increased risk of lung cancer and death. The signs of CP/CF are difficult to assess. For optimal patient care, more education and awareness about the signs of CP/CF are needed in order to avoid missing the diagnosis.

Anonymous Patient Answer

Can cystic fibrosis be cured?

There is not enough evidence to answer the question of "whether" CF can be cured. It is conceivable, however, that in some situations, CF can be managed on the whole, in many respects, as a curable disease\n

Anonymous Patient Answer

What causes cystic fibrosis?

There is currently no single explanation for the cause of cystic fibrosis. Genetic and environmental factors play a part, and some of the most important evidence is circumstantial. The most recent theory is of a complex multifactorial cause, with infectious, environmental and genetic factors all probably playing a part in the development of the disease. The most credible data suggests a genetic component.

Anonymous Patient Answer

How does elx/tez/iva work?

These data show that elx/tez/iva does not act as an 'aerosolizing' agent, and thus does not affect bacterial numbers in the airway of patients, and that it has no effect on CF patients' outcomes.

Anonymous Patient Answer

Has elx/tez/iva proven to be more effective than a placebo?

For elx/tez/iva compared with placebo for both the prevention and treatment of clinical exacerbations, it was safer and, based on clinical trials, seemed to have a greater effect. No significant differences between treatment groups were observed regarding complications/relapses and lung function at the end of treatment, but longer-term follow-up will be necessary before drawing strong conclusions. Elx/tez/iva is the only approved treatment for elavulin, to date, and can be prescribed and purchased outside prescription drug programs. Elx/tez/iva is not approved in the US.

Anonymous Patient Answer

Is elx/tez/iva safe for people?

The most common reason for discontinuation with elx/tez/iva in this study was loss of adherence due to lack of information about side effects, especially diarrhea. It may be that it was not recognized as a true diarrhea medication in trials, and that side effects were not as pronounced as they may have been outside clinical trials. However further studies and research into the use of elx/tez/iva are still needed to gain more insight on treatment effectiveness and side effects before any conclusions can safely be given.

Anonymous Patient Answer

Does cystic fibrosis run in families?

Genetic counseling can be provided to patients and their families. Genetic counseling should include information regarding the prevalence of CF. The rationale for the need for careful surveillance includes the identification of atypical CF patients who may not be suspected to have CF even though they have a very similar clinical presentation.

Anonymous Patient Answer

What is the average age someone gets cystic fibrosis?

The average age people with CF have symptoms is 36.6 years of age. Older than 36.6 years, there is some degree of survivorship. It is critical that clinicians and caregivers are aware that while most do reach this age, some do not. It is also important to note that since the mean age of onset is only ~38 years in the US for those with a genetic variant in the CF transmembrane conductance regulator, an average age of 46 was estimated for the typical presentation of CF in the UK (2011).

Anonymous Patient Answer

What are the latest developments in elx/tez/iva for therapeutic use?

The Eltex elixir is the latest version of its type. They are an improvement in many ways. The elution process has been improved with the addition of sodium lauryl sulfate. It is now more efficient than the original formulation and is available in the United States\n

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Cystic Fibrosis by sharing your contact details with the study coordinator.